Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00879619 · ClinicalTrials.gov registry record · Phase 1
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
A Phase 1 study, sponsored by John P. Fruehauf.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00879619 is a Phase 1 study that was terminated before completion, run by John P. Fruehauf. The registered enrollment target is 4 participants.
The verdict
NCT00879619, a Phase 1 study, was terminated before completion, sponsored by John P. Fruehauf.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel and prednisone together with sunitinib malate may kill more tumor cells. PURPOSE: This pilot phase I/II trial studies the side effects and best way to give docetaxel and prednisone together with sunitinib malate and to see how well it works in treating patients with prostate cancer that progressed after hormone therapy.
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00879619
The ClinicalTrials.gov registry entry for NCT00879619 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John P. Fruehauf, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00879619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00879619 about?
NCT00879619 is a clinical study titled "Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients". RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth...
What is the current status of trial NCT00879619?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-07. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00879619?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00879619?
This trial is sponsored by John P. Fruehauf, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.